EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI. Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). Change the drug administration maybe prolong patients PFS and evently prolong OS.
Name: history dataDescription: history data of PFS after 1st line or second line therayType: Other
weekly use erolotinib vs history data
There is one SNP
Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). --- T790M ---
EGFR-TKI Resistant Mutation Carcinoma, Non-Small-Cell Lung 1st generation EGFR-TKI has reversible binding to EGFR, it also bind to T790M in a high dose which is account about 60% patients acquired resistance to the drug. --- T790M ---
Resistance patients may be benefit to a bolus drug use to block T790M gene. --- T790M ---